Alastair  Garfield net worth and biography

Alastair Garfield Biography and Net Worth

Chief Scientific Officer of Rhythm Pharmaceuticals

Dr. Alastair Garfield joined Rhythm in July 2024 as Chief Scientific Officer. He rejoins Rhythm after serving as Senior Vice President and Head of Translational Sciences and Strategy at Rectify Pharma, where he helped deliver first-in-class therapeutics for rare disease. Prior to joining Rectify, Dr. Garfield was Senior Vice President and Head of Translational Research at Rhythm. He also held roles at Pfizer, where he was a lab head in the Cardiovascular Metabolic Disease Research Unit and led novel obesity target identification.

Dr. Garfield’s holds a first-class degree in molecular and cellular biology and a Ph.D. in molecular genetics from the University of Bath, UK. His postdoctoral fellowships at the University of Cardiff, UK and University of Cambridge, UK focused on neural pathways and genes underlying mammalian energy balance. As an assistant professor at the University of Edinburgh, UK and visiting professor Harvard Medical School, Dr. Garfield’s independent research expanded the field’s understanding of the hypothalamic melanocrotinergic networks regulating metabolism, body weight and appetite. His research has been published in leading scientific journals including Nature, Nature Neuroscience, Neuron, and Cell Metabolism. Dr Garfield has authored numerous original research and review articles on the MC4R pathway, including “Melanocortin-4 receptor-regulated energy homeostasis,” which was published in Nature Neuroscience in 2016 (https://pubmed.ncbi.nlm.nih.gov/26814590/).

What is Alastair Garfield's net worth?

The estimated net worth of Alastair Garfield is at least $330.42 thousand as of July 2nd, 2025. Dr. Garfield owns 3,126 shares of Rhythm Pharmaceuticals stock worth more than $330,418 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Garfield may own. Learn More about Alastair Garfield's net worth.

How do I contact Alastair Garfield?

The corporate mailing address for Dr. Garfield and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Alastair Garfield's contact information.

Has Alastair Garfield been buying or selling shares of Rhythm Pharmaceuticals?

Alastair Garfield has not been actively trading shares of Rhythm Pharmaceuticals within the last three months. Most recently, Alastair Garfield sold 1,319 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $64.81, for a transaction totalling $85,484.39. Following the completion of the sale, the insider now directly owns 3,126 shares of the company's stock, valued at $202,596.06. Learn More on Alastair Garfield's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Alastair Garfield (Chief Scientific Officer), Christopher German (CAO), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 35 times. They sold a total of 306,594 shares worth more than $22,050,831.72. The most recent insider tranaction occured on October, 30th when insider Joseph Shulman sold 9,748 shares worth more than $1,123,359.52. Insiders at Rhythm Pharmaceuticals own 6.1% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 10/30/2025.

Alastair Garfield Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/2/2025Sell1,319$64.81$85,484.393,126View SEC Filing Icon  
See Full Table

Alastair Garfield Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Alastair Garfield's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $105.70
Low: $102.76
High: $107.57

50 Day Range

MA: $104.32
Low: $95.89
High: $113.89

2 Week Range

Now: $105.70
Low: $45.90
High: $116.00

Volume

575,890 shs

Average Volume

682,944 shs

Market Capitalization

$7.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96